Patients with a nonrejection-related diagnosis according to the 2019 Banff classification who were reclassified as MVI, ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

Notably, the findings from this work may provide novel insight into the underlying mechanisms of PAD and, perhaps, have prevention or therapeutic ...

Researchers determined patients with PNH demonstrated poorer HRQoL and greater functional impairment than observed in the general population.

Lipocine (LPCN) announced that the FDA has recently informed sponsors of approved testosterone products about class-wide labeling changes. This ...